Fate Therapeutics

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Fate Therapeutics reports strong financials, advances innovative CAR cell therapies

Fate Therapeutics reported strong financial performance with a focus on advancing key programs and innovative CAR NK and CAR T-cell products.
The company faces challenges in managing costs post-collaboration termination and navigating increased research and development expenses.
Opportunities lie in advancing IND submissions, exploring novel therapy combinations, and enhancing transparency through data disclosures and collaboration.
Overall, Fate Therapeutics showcases strength in leveraging proprietary platforms for differentiated therapies and commitment to advancing next-gen CAR T-cell products.

Fate Therapeutics reports robust Q1 revenue growth and strategic focus

Fate Therapeutics reported strong Q1 revenue growth but faces challenges with workforce reduction and disclosure commitments
The company's financial position is robust, with a focus on advancing key CAR NK and CAR T-cell programs in 2023
Opportunities lie in exploring autoimmune applications, biomarker evaluation, and ADR technology superiority for future growth
Navigating FDA requirements and study design complexities remain key challenges for program advancement

Fate Therapeutics navigates revenue challenges, advances CAR cell programs

Fate Therapeutics faced revenue challenges in Q2 but maintained a strong financial position with significant cash reserves.
Progress in advancing CAR-NK and CAR-T cell programs signals potential growth opportunities in the oncology space.
Clear guidance on operating expenses and strategic IND submissions demonstrate a proactive approach to future growth.
Addressing revenue diversification, cost management, and effective clinical development will be key focus areas for sustained success.

Fate Therapeutics advances innovative cell therapies amidst financial stability

Fate Therapeutics demonstrated strong progress in product development and financial management, positioning them as a leader in innovative cell therapies.
While facing challenges in revenue dynamics and managing expenses, the company has opportunities to drive value through upcoming milestones and pioneering treatment approaches.
Clear communication, strategic partnerships, and a focus on clinical proof of concept will be crucial for Fate Therapeutics to navigate the competitive landscape and capitalize on opportunities for growth.
The company's commitment to advancing novel therapies in oncology and autoimmunity underscores their dedication to addressing unmet medical needs and shaping the future of patient care.

Fate Therapeutics reports solid financials, eyes autoimmune therapy expansion

Fate Therapeutics showcases strong financial position but faces expense challenges.
Their off-the-shelf cell therapy programs exhibit promising efficacy and safety profiles.
Opportunities lie in expanding clinical investigations and exploring autoimmune indications.
Challenges include high operating expenses and the need for therapy differentiation.

Fate Therapeutics excels in autoimmune therapy innovation amidst financial stability

Fate Therapeutics showcased strong performance in Q1 2024 with promising data from FT819 and FT522 programs in autoimmune diseases.
While facing high operating expenses, the company maintains financial stability and aims for continued growth and innovation in cellular therapy.
Challenges in differentiation and clinical translation are met with opportunities for expanded indications and novel treatment approaches in autoimmune settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novel H 2 CasMab-2 Antigen Binding Domain Shown to Preferentially Target HER2 Expressed on Tumor Cells in Preclinical Studies

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant Transformation

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2024 the Company granted restricted stock units (RSUs) representing 20,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2024 the Company granted restricted stock units (RSUs) representing 16,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employee being continuously employed by the Company through each vesting date.

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York.

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

Why Is Fate Therapeutics (FATE) Up 18.7% Since Last Earnings Report?

Fate Therapeutics (FATE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Fate Therapeutics (FATE) Rating Upgrade to Buy

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

Fate Therapeutics (FATE) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago.

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Cipher Mining

Anywhere Real Estate Inc

Hovnanian Enterprises

QuantumScape

The rotation to small caps stocks started on July 11th and hasn't let up yet. As of noon today, the small cap-focused Russell 2000 has outperformed the S&P 500 by 12% and the Nasdaq-100 by 16% over that period.

5 Small Cap Stocks That Popped 30% In Less than 10 Days

AbCellera Biologics

The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a dozen experimental drugs in clinical-stage development.

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

PHILADELPHIA , June 13, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Fate Therapeutics, Inc. (NASDAQ: FATE) ("Fate") on behalf of the company's long-term investors. Recently an amended securities fraud complaint was filed against Fate on behalf of certain investors who purchased shares of the company's stock between August 5, 2020 and January 5, 2023.

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York.

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

Fate Therapeutics, Inc. (NASDAQ:FATE ) Q1 2024 Results Conference Call May 9, 2024 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Bob Valamehr - Chief Research and Development Officer Conference Call Participants Michael Yee - Jefferies Ashiq Mubarack - Citi Jeff LaRosa - Leerink Partners Rohit Bhasin - Morgan Stanley Li Watsek - Cantor Fitzgerald Greg Williams - TD Cowen Carolina Ibanez-Ventoso - Stifel Alex Bouilloux - Barclays Yanan Zhu - Wells Fargo Securities Bill Maughan - Canaccord Genuity Ethan Markowski - Needham & Company Operator Welcome to the Fate Therapeutics First Quarter 2024 Financial Results Conference Call [Operator Instructions]. This call is being webcast live on the Investors section of Fate's Web site at fatetherapeutics.com.

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

Fate Therapeutics (FATE) came out with a quarterly loss of $0.47 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.19 per share a year ago.

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

Pre-treatment Sample of Patient's Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Fate Therapeutics has a lot of potential in the cell therapy market, with multiple pipeline projects in development. Their flagship allogeneic CAR T-cell project, FT819, has shown promising results in early reports, particularly in patients with B-cell lymphoma. The company is also developing NK cell immunotherapies, with one program, FT522, showing positive results in patients with B-cell lymphoma. However, their cash burn rate remains high, which could be a risk.

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Fate Therapeutics has faced setbacks, including the termination of a partnership with Janssen Pharmaceuticals, but upcoming clinical milestones could reset the bull thesis. The company's iPSCs technology creates renewable off-the-shelf cell therapies for hematological malignancies and solid tumors. Fate Therapeutics has a healthy cash position and is expected to report positive data from clinical trials, potentially leading to exponential growth and significant market share.

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.

Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced the pricing of an underwritten offering of 14,545,454 shares of its common stock at an offering price of $5.50 per share. The offering includes participation from new and existing institutional investors, including Adage Capital Partners LP., Boxer Capital, Deep Track Capital, OrbiMed, Suvretta Capital and a life-sciences focused investor.

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:

News for Fate Therapeutics Stock (FATE)